Phase 1 Trial: APG-5918 an EED Inhibitor for Prostate Cancer Therapy
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 Trial: CTS2190 Targets Advanced Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 trial: SYN818 Shows Promise for Prostate Cancer Patients With HRR Genetic Mutations
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 Trial: NXP900 for Overcoming Resistance in Advanced Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 Recruiting: ABBV-969, A Novel Bispecific Antibody Drug Conjugate for Advanced Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 Trial: GDC-2992, A Novel Dual-Action AR Degrader Aiming to Overcome Resistance in Advanced Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 Recruiting: IMP1734 (EIK1003), A New PARP1 Inhibitor for mCRPC
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 Recruiting: GSK5764227 Targets B7-H3 in mCRPC
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxGrape Seed Extract Shows Potential to Slow Prostate Cancer Progression
/0 Comments/in Clinical Trial, Non-Metastatic, Phase 2/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC AI ai in healthcare alphafold antibody-drug conjugate apalutamide ASCO 2025 ATM bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T clinical trial clinical trials crispr CYP11A1 inhibitor darolutamide drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus personalized medicine Pluvicto prostate cancer PSMA radioligand therapy radiopharmaceuticals real-world data theranostics
Latest Posts
- LYA914: A Novel Oral PROTAC Targeting Androgen Receptor Variants in Prostate Cancer July 30, 2025
- Phase 1/2 Trial for DS-3939a: A Novel TA-MUC1–Directed ADC for Advanced Prostate Cancer and Beyond July 29, 2025
- AI Platform Aims to Revolutionize Cancer Immunotherapy July 28, 2025
- FDA Clears First-in-Human Phase 1 Trial: RV-01 Targeting Solid Tumors July 28, 2025